Xenacare Holdings Inc.(fka XCHO)

[stervc]

Sheff, with XCHO, The ASCO & Cobroxin...

That was an awesome piece of intel you posted with your conversation you had with one of your doctors. The American Society of Clinical Oncology (ASCO) has an outstanding piece of clinical data that all should review that confirms that Cobroxin has outperformed Ultram (tramadol hydrochloride) and ibuprofen. I think since you have been in contact with the company, I think you should call him to make sure he is aware of this as this is something that I think everyone within the field of medicine should be made aware of.

Pay particular attention to what’s in bold and underlined below:
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1762
Author(s):

Jian-Ming Xu, San-Tai Song, Feng-Yi Feng, Fu-Lin Huang, Yan Yang, Guang-Ru Xie, Li-Gong Xu, Angelo Paradiso, Beijing 307 Hospital Cancer Center, Beijing, China; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Jiangsu Province Cancer Hospital, Nanjing, China; Kunming the PLA General Hospital, Kunming, China; Tianjin Cancer Hospital, Tianjin, China; Cancer Hospital, Shanghai Medical University, Shanghai, China; National Cancer Institute, Bari, Italy.


Abstract:

Background: Cobrotoxin produces intense analgesia, but the onset of response is slow, which hampered its clinical use in cancer pain. However, it is unknown whether the compound cobrotoxin (compound Keluoqu, CKLQ), a combination of cobrotoxin, tramadol hydrochloride and ibuprofen is a suitable formulation for cancer pain or not. Methods: We enrolled patients who had chronic moderate to severe cancer pain in a randomized, multicenter trial. Of the 230 eligible patients, 119 were randomized to double-blind, cross-over study, 111 entered an open-label study. In cross-over study, 59 patients were randomized to dose CKLQ, placebo, tramadol hydrochloride (group A), 61 to tramadol hydrochloride, placebo, CKLQ (group B) in order for one time. Patients in the open-label study were given the option to continue taking CKLQ for 7 days as long as they felt satisfactory in pain relief. Results: One hundred and eight patients completed the cross-over study with three units, and 11 did not. The overall relief rate of CKLQ in cross-over study was 93/111 (83.7%), higher than 75/110 (68.2%) of tramadol hydrochloride (P=0.011) and 39/111 (35.1%) of placebo (P<0.001). The mean duration of response of CKLQ was significantly long among the three agents (P<0.001). Of the 35 patients who did not respond to tramadol hydrochloride, 27(77.1%) responded to CKLQ. And of the 18 who did not respond to CKLQ, 8(55.6%) obtained satisfactory pain control to tramadol hydrochloride. In open-label study, the overall relief rate of the first-dose CKLQ was 99/111 (89.2%). The trends toward reduction in complete relief (CR), increase in partial relief (PR) and significant decrease in duration of response were observed after continuous treatment with at least 10 times of CKLQ dose. The frequency of adverse events of CKLQ was similar to that of tramadol hydrochloride. Conclusions: CKLQ might be an effective analgesic for treatment of chronic moderate to severe cancer pain as an alternative to tramadol hydrochloride. …

************************************************************

v/r
Sterling